From Wikipedia, the free encyclopedia
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Clinical data
ATC code
  • none
CAS Number
  • none
Chemical and physical data
Molar mass145349.06 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma.[1][2] As of December 2011, it is undergoing Phase I/II clinical trials.[3] When used with milatuzumab it showed activity.[4]

This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.[5]

In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP).[6] A phase II trial is planned to run for 5 years.[6]

See also[edit]


  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
  2. ^ Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH (October 2009). "CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas". Blood. 114 (18): 3864–71. doi:10.1182/blood-2009-06-228890. PMC 2773491. PMID 19710501.
  3. ^ Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at
  4. ^ Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, et al. (June 2015). "The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma". British Journal of Haematology. 169 (5): 701–10. doi:10.1111/bjh.13354. PMC 7297055. PMID 25847298.
  5. ^ Zibelman M, Borghaei H, Olszanski AJ (2014). "Harnessing Innate Immunity". In Dubel S, Reichert JM (eds.). Handbook of Therapeutic Antibodies (2nd ed.). John Wiley & Sons. p. 791. doi:10.1002/9783527682423.ch27. ISBN 978-3-527-68244-7.
  6. ^ a b "FDA grants orphan drug designation to veltuzumab for ITP". HemOnc Today. August 4, 2015.